Oxular presents at Eyecelerator

Our CEO, Tom Cavanagh, presented an overview of Oxular’s retinal therapeutics platform at Eyecelerator, during AAO 2021.

It was a pleasure to share this update, with a specific focus on OXU-001, Oxular’s lead program investigating a long-lasting, suprachoroidally administered treatment for DME. You can read Tom’s presentation below.

 
Scroll to Top